- Home
- KOS vs BCYC Comparison
KOS vs BCYC Comparison
Compare KOS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- BCYC
- Stock Information
- Founded
- KOS 2003
- BCYC 2009
- Country
- KOS United States
- BCYC United Kingdom
- Employees
- KOS N/A
- BCYC N/A
- Industry
- KOS Oil & Gas Production
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- KOS Energy
- BCYC Health Care
- Exchange
- KOS Nasdaq
- BCYC Nasdaq
- Market Cap
- KOS 698.3M
- BCYC 565.5M
- IPO Year
- KOS 2011
- BCYC 2019
- Fundamental
- Price
- KOS $1.67
- BCYC $7.90
- Analyst Decision
- KOS Hold
- BCYC Buy
- Analyst Count
- KOS 5
- BCYC 11
- Target Price
- KOS $3.40
- BCYC $22.91
- AVG Volume (30 Days)
- KOS 10.0M
- BCYC 304.5K
- Earning Date
- KOS 11-03-2025
- BCYC 10-31-2025
- Dividend Yield
- KOS N/A
- BCYC N/A
- EPS Growth
- KOS N/A
- BCYC N/A
- EPS
- KOS N/A
- BCYC N/A
- Revenue
- KOS $1,488,836,000.00
- BCYC $19,281,000.00
- Revenue This Year
- KOS N/A
- BCYC N/A
- Revenue Next Year
- KOS $15.84
- BCYC N/A
- P/E Ratio
- KOS N/A
- BCYC N/A
- Revenue Growth
- KOS N/A
- BCYC N/A
- 52 Week Low
- KOS $1.39
- BCYC $6.10
- 52 Week High
- KOS $4.22
- BCYC $25.77
- Technical
- Relative Strength Index (RSI)
- KOS 52.21
- BCYC 49.34
- Support Level
- KOS $1.41
- BCYC $7.65
- Resistance Level
- KOS $1.51
- BCYC $8.42
- Average True Range (ATR)
- KOS 0.09
- BCYC 0.51
- MACD
- KOS 0.00
- BCYC -0.08
- Stochastic Oscillator
- KOS 56.67
- BCYC 17.50
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.